Received: 28 April 2021
Accepted: 9 August 2021
First Online: 23 August 2021
: Refer to reference [CitationRef removed], ExternalRef removed identifier NCT04392219.
: Not applicable.
: Wendy Holman, Wayne Homan, Stacy McIntosh, and Wendy Painter are employees of Ridgeback Biotherapeutics, which funded the study. George Painter holds a number of patents that are relevant to EIDD-2801 (molnupiravir)—see separately submitted ICMJE form. Jim Bush and Oren Cohen are employees of Covance, the CRO chosen by Ridgeback to assist in the execution of the study described.